These drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Other potential risks include: Acute pancreatitis Gallbladder disease (cholelithiasis, cholecystitis) Acute kidney injury Hypersensitivity reactions Patients should be monitored for persistent abdominal pain, changes in renal function, and other signs that may require discontinuation or additional workup
L., Saina, M., Trevisiol, M., Cristante, T
Most of my patients who have lost weight with GLP-1 agonists have had gradual weight loss over months
Whats the plan if I cant continue? said Golden, an obesity medicine specialist in Watertown, Wisconsin
Many peptide researchers are interested in conducting ipamorelin studies